This is an oral medication in tablet form.
Mavenclad® is a compound that targets certain types of white blood cells (lymphocytes) that drive the immune attack in MS. It temporarily reduces the number of both T and B lymphocytes without continuous suppression of the immune system.
Mavenclad® is approved by the FDA for adults with relapsing forms of multiple sclerosis, to include relapsing-remitting disease and active secondary progressive disease. Because of its safety profile, use of Mavenclad is generally recommended for patients who have had an inadequate response to, or are unable to tolerate, an alternate drug indicated for the treatment of MS.
to read the Prescribing Information for healthcare providers.
to read the Medication Guide for patients.
Financial Assistance ProgramMS LifeLines®